Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
16 Maggio 2024 - 2:05PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced it will present data from two real-world
studies at the 2024 Digestive Disease Week (DDW) meeting in
Washington, DC, highlighting the value of the company’s Shield™
test in colorectal cancer (CRC) screening.
“One in three eligible American adults have not been screened
for CRC, in part because the currently available methods are
unpleasant or inconvenient,” said AmirAli Talasaz, co-CEO of
Guardant Health. “The data we will share at DDW underscores the
important role that our Shield blood test can have in both
improving screening rates and in detecting more colorectal cancer
at an early stage, when it is most treatable. We look forward to
sharing this important data at DDW.”
Guardant Health 2024 DDW Poster Presentations
Abstract
Session
Title
May 20, 2024, 12:30 – 1:30 p.m. ET
# Mo1026
Poster Session: 8000
Integration of a blood-based colorectal
cancer screening test into routine radiology imaging visits
improves overall screening rates
# Mo1196
Poster Session: 8055
New screening tests, same challenge: an
early look at colonoscopic follow-up after abnormal blood-based
colorectal cancer screening results in a real world setting
Guardant Health unveiled initial results from the ECLIPSE study
validating the performance of the Shield test at the 2023 DDW
meeting. The data served as the basis for Guardant Health’s
submission of a premarket approval (PMA) application to the FDA,
and the full study results have since been published in the March
2024 issue of The New England Journal of Medicine. An FDA Advisory
Panel is scheduled to review the PMA application on May 23.
The full abstracts for Guardant Health and a list of all
abstracts being presented at the meeting will be available at the
DDW website.
For information and updates from the meeting, follow Guardant
Health on LinkedIn, X (Twitter) and Facebook.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2023, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240516838593/en/
Investor Contact: Zarak Khurshid
investors@guardanthealth.com
Media Contact: Mike Weist press@guardanthealth.com +1
650-647-3643
Grafico Azioni Guardant Health (NASDAQ:GH)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Guardant Health (NASDAQ:GH)
Storico
Da Set 2023 a Set 2024